IPP Bureau
RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer
By IPP Bureau - July 03, 2025
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability
By IPP Bureau - July 03, 2025
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil
By IPP Bureau - July 02, 2025
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Cadila Pharmaceuticals launches Bilacad Dex Syrup
By IPP Bureau - July 02, 2025
A triple-action Formula for comprehensive respiratory relief
Lupin carves out LupinLife Consumer Healthcare
By IPP Bureau - July 02, 2025
AstraZeneca Pharma India receives permission to import Durvalumab Solution
By IPP Bureau - July 02, 2025
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel
By IPP Bureau - July 02, 2025
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease
By IPP Bureau - July 02, 2025
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Glaukos receives EU MDR certification for iStent infinite
By IPP Bureau - July 02, 2025
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
AbbVie to acquire Capstan Therapeutics for $2.1 billion
By IPP Bureau - July 01, 2025
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer
By IPP Bureau - July 01, 2025
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Moderna announces promising efficacy results from mRNA flu vaccine trial
By IPP Bureau - July 01, 2025
mRNA-1010 demonstrated superior relative vaccine efficacy
Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery
By IPP Bureau - July 01, 2025
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
PerkinElmer appoints Payal Agrawaal as MD - India & South Asia
By IPP Bureau - July 01, 2025
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
Briefs: Lyfius Pharma and Aurobindo Pharma
By IPP Bureau - July 01, 2025
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
